<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - AMINOPHYLLINE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>AMINOPHYLLINE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#allergyAndCrossSensitivity" data-toggle="tab">Allergy and cross sensitivity</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Severe acute asthma in patients not previously treated with theophylline</span>,
            </h4>
            <p class="specificity"><span class="route">By slow intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                250&#8211;500 mg (max. per dose 5 mg/kg), to be followed by intravenous infusion.</li>
              <li class="dose child"><strong>For children </strong><br/>
                5 mg/kg (max. per dose 500 mg), to be followed by intravenous infusion.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Severe acute asthma</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                500&#8211;700 micrograms/kg/hour, adjusted according to plasma-theophylline concentration.</li>
              <li class="dose adult"><strong>For adults elderly</strong><br/>
                300 micrograms/kg/hour, adjusted according to plasma-theophylline concentration.</li>
              <li class="dose child"><strong>For children 1 month&#8211;11 years</strong><br/>
                1 mg/kg/hour, adjusted according to plasma-theophylline concentration.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                500&#8211;700 micrograms/kg/hour, adjusted according to plasma-theophylline concentration.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Severe acute exacerbation of chronic obstructive pulmonary disease in patients not previously treated with theophylline</span>,
            </h4>
            <p class="specificity"><span class="route">By slow intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                250&#8211;500 mg (max. per dose 5 mg/kg), to be followed by intravenous infusion.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Severe acute exacerbation of chronic obstructive pulmonary disease</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                500&#8211;700 micrograms/kg/hour, adjusted according to plasma-theophylline concentration.</li>
              <li class="dose adult"><strong>For adults elderly</strong><br/>
                300 micrograms/kg/hour, adjusted according to plasma-theophylline concentration.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Chronic asthma</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using modified-release medicines</span></p>
            <ul class="doses">
              <li class="dose child"><strong>For children (body-weight 40 kg and above)</strong><br/>
                Initially 225 mg twice daily for 1 week, then increased if necessary to 450 mg twice daily, adjusted according to plasma-theophylline concentration.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Reversible airway obstruction</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using modified-release medicines</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults (body-weight 40 kg and above)</strong><br/>
                Initially 225 mg twice daily for 1 week, then increased if necessary to 450 mg twice daily, adjusted according to plasma-theophylline concentration.</li>
            </ul>
          </section>
        </section>
        
            <section class="doseAdjustments">
                <h3>Dose adjustments due to interactions</h3>
              <p>Dose adjustment may be necessary if smoking started or stopped during treatment.</p>
            </section>
        
        
            <section class="extremesOfBodyWeight">
                <h3>Doses at extremes of body-weight</h3>
              <p>To avoid excessive dosage in obese patients, dose should be calculated on the basis of ideal weight for height.</p>
            </section>
        
            <section class="pharmacokinetics">
              <h3>Pharmacokinetics</h3>
              <p>Aminophylline is a stable mixture or combination of theophylline and ethylenediamine; the ethylenediamine confers greater solubility in water.</p><p>Theophylline is metabolised in the liver. The plasma-theophylline concentration is increased in heart failure, hepatic impairment, and in viral infections. The plasma-theophylline concentration is decreased in smokers, and by alcohol consumption. Differences in the half-life of aminophylline are important because the toxic dose is close to the therapeutic dose.</p>
            </section>
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Neonatal irritability and apnoea have been reported.</p><p>Theophylline can be taken as normal during pregnancy as it is particularly important that asthma should be well controlled during pregnancy.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="doseAdjustments">
              <p>Reduce dose.</p>
            </section>
      </section>



      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>notKnown:</strong> Arrhythmias (especially if given rapidly by intravenous injection), CNS stimulation, convulsions (especially if given rapidly by intravenous injection), diarrhoea, erythema (due to allergy to ethylenediamine), exfoliative dermatitis (due to allergy to ethylenediamine), gastric irritation, headache, hypotension (especially if given rapidly by intravenous injection), insomnia, nausea, palpitation, tachycardia, urticaria (due to allergy to ethylenediamine), vomiting,
              </p>
        
        
            <section class="advice">
                <h3>Hypokalaemia</h3>
              <p>Potentially serious hypokalaemia may result from beta<sub>2</sub> agonist therapy. Particular caution is required in severe asthma, because this effect may be potentiated by concomitant treatment with theophylline and its derivatives, corticosteroids, and diuretics, and by hypoxia. Plasma-potassium concentration should therefore be monitored in severe asthma.</p>
            </section>
        
            <section class="overdosageInformation">
              <p>Theophylline and related drugs are often prescribed as modified-release formulations and toxicity can therefore be delayed. They cause vomiting (which may be severe and intractable), agitation, restlessness, dilated pupils, sinus tachycardia, and hyperglycaemia. More serious effects are haematemesis, convulsions, and supraventricular and ventricular arrhythmias. Severe hypokalaemia may develop rapidly.</p><p>For specific details on the management of poisoning, see <i>Theophylline</i>, under <xref format="dita" href="#PHP78558" type="bookmark" namespace="/treatment-summaries/emergency-treatment-of-poisoning">Emergency treatment of poisoning</xref>.</p>
            </section>
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in children</h3>
              <p>For <i>intravenous infusion</i>, dilute to a concentration of 1&#8239;mg/mL with Glucose 5% <i>or</i> Sodium Chloride 0.9%.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in adults</h3>
              <p>For <i>intravenous infusion</i>, give continuously in Glucose 5% <i>or</i> Sodium Chloride 0.9%.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>For <i>intravenous injection</i>, give <b>very slowly</b> over at least 20 minutes (with close monitoring).</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intramuscular</ph> use</h3>
              <p>Aminophylline is too irritant for intramuscular use.</p>
            </section>
      </section>




      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Arrhythmias following rapid intravenous injection
          </li>
          <li>
            cardiac arrhythmias or other cardiac disease
          </li>
          <li>
              <strong>:</strong>
            elderly (increased plasma-theophylline concentration) in adults
          </li>
          <li>
            epilepsy
          </li>
          <li>
            fever
          </li>
          <li>
            hypertension
          </li>
          <li>
            hyperthyroidism
          </li>
          <li>
            peptic ulcer
          </li>
          <li>
            risk of hypokalaemia
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

          <h3>Therapeutic drug monitoring</h3>
        
            <section class="therapeuticDrugMonitoring">
              <h3 class="specificity">In adults</h3>
              <p>Aminophylline is monitored therapeutically in terms of plasma-theophylline concentrations.</p><p>Measurement of plasma-theophylline concentration may be helpful and is <b>essential</b> if intravenous aminophylline is to be given to patients who are already taking theophylline, because serious side-effects such as convulsions and arrhythmias can occasionally precede other symptoms of toxicity.</p><p>In most individuals, a plasma-theophylline concentration of 10&#8211;20&#8239;mg/litre (55&#8211;110&#8239;micromol/litre) is required for satisfactory bronchodilation, although a lower plasma-theophylline concentration may be effective. Adverse effects can occur within the range 10&#8211;20mg/litre and both the frequency and severity increase at concentrations above 20&#8239;mg/litre.</p>
            </section>
            <section class="therapeuticDrugMonitoring">
              <h3 class="specificity">In children</h3>
              <p>Aminophylline is monitored therapeutically in terms of plasma-theophylline concentrations.</p><p>Measurement of plasma-theophylline concentration may be helpful and is <b>essential</b> if a loading dose of intravenous aminophylline is to be given to children who are already taking theophylline, because serious side-effects such as convulsions and arrhythmias can occasionally precede other symptoms of toxicity.</p><p>In most individuals, a plasma-theophylline concentration of 10&#8211;20&#8239;mg/litre (55&#8211;110&#8239;micromol/litre) is required for satisfactory bronchodilation, although a lower plasma-theophylline concentration of 5&#8211;15&#8239;mg/litre may be effective. Adverse effects can occur within the range 10&#8211;20&#8239;mg/litre and both the frequency and severity increase at concentrations above 20&#8239;mg/litre.</p>
            </section>
            <section class="therapeuticDrugMonitoring">
              <p>If aminophylline is given intravenously, a blood sample should be taken 4&#8211;6 hours after starting treatment.</p>
            </section>
            <section class="therapeuticDrugMonitoring">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>It is recommended that plasma-theophylline concentration is measured in all patients receiving intravenous aminophylline.</p>
            </section>
            <section class="therapeuticDrugMonitoring">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>Plasma-theophylline concentration is measured 5 days after starting oral treatment and at least 3 days after any dose adjustment. A blood sample should usually be taken 4&#8211;6 hours after an oral dose of a modified-release preparation (sampling times may vary&#8212;consult local guidelines).</p>
            </section>
        
      </section>

      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <h3 class="specificity">In children</h3>
              <p>Aminophylline injection not licensed for use in children under 6 months.</p>
            </section>
      </section>

      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
                <h3>Modified release</h3>
              <p>The rate of absorption from modified-release preparations can vary between brands. If a prescription for a modified-release oral aminophylline preparation does not specify a brand name, the pharmacist should contact the prescriber and agree the brand to be dispensed. Additionally, it is essential that a patient discharged from hospital should be maintained on the brand on which that patient was stabilised as an in-patient.</p>
            </section>
            <section class="prescribingAndDispensingInformation">
              <p>Patients taking oral theophylline or aminophylline should not normally receive a loading dose of intravenous aminophylline.</p><p>Consider intravenous aminophylline for treatment of severe and life-threatening acute asthma only after consultation with senior medical staff.</p>
            </section>
      </section>








      <section class="tab-pane" id="allergyAndCrossSensitivity">
        <h2>Advice regarding allergies and cross sensitivities</h2>

        
            <section class="crossSensitivity">
              <p>Allergy to ethylenediamine can cause urticaria, erythema, and exfoliative dermatitis; hypotension, arrhythmias, and convulsions especially if given rapidly by intravenous injection.</p>
            </section>
      </section>

      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of AMINOPHYLLINE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            solution for infusion,
            suppository,

            <div id="PHP76220"><a href="../medicinalForm/PHP76220.html" data-target="#PHP76220" data-action="load">Modified-release tablet</a></div>
            <div id="PHP76227"><a href="../medicinalForm/PHP76227.html" data-target="#PHP76227" data-action="load">Solution for injection</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
